RxDoctor Payments Data

Bronwyn Leblanc, MD

Nephrology · Metairie, LANPI 1922448372

Payments from drug & device makers

$1,970in general payments, 2019–2025

Across 70 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$317
  • Vifor Pharma, Inc.$313
  • Bayer$300
  • Amgen$212
  • Akebia Therapeutics Inc$139
  • Aurinia Pharma U.S., Inc.$133
  • plus $556 from 9 others

What the payments were for

  • Food & beverage$1,82192%
  • Education$1498%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,970 in reported general payments places this provider in the 45th percentile of 206 nephrology providers in Louisiana.

See all nephrology providers in Louisiana

Medicare billing

Part B allowed, 2024
$38,109
Medicare patients
94
Services billed
418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin57$42,514
FarxigaDapagliflozin Propanediol34$24,656
VeltassaPatiromer Calcium Sorbitex23$20,517
KerendiaFinerenone18$19,668
LokelmaSodium Zirconium Cyclosilicate25$10,956
Potassium Citrate ErPotassium Citrate19$1,873
Sevelamer Carbonate24$1,370
Calcitriol59$1,047
Allopurinol112$696
Colchicine13$487
Losartan Potassium64$480
Midodrine Hcl11$427
Furosemide90$310
Potassium Chloride25$255
Spironolactone22$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$317$35,61259 claims
BayerKerendia$300$19,66818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 206 nephrology providers in Louisiana.

Other nephrology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →